Status:
RECRUITING
Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
Lead Sponsor:
CHU de Reims
Conditions:
Antiphospholipid Syndrome
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades. In individuals under the age of 65, the etiologies of ischemic stroke (IS) are diverse, and m...
Detailed Description
Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades, particularly in acute-phase management. In 80% of cases, stroke is ischemic (IS), and the eti...
Eligibility Criteria
Inclusion
- inclusion criteria :
- patients aged 65 and over during the inclusion phase
- hospitalized for a TIA/ischemic stroke in neurology or internal medicine department during the inclusion phase
- affiliated with social security system exclusion criteria :
- patients under 65 years old
- under legal guardianship, curatorship, or tutorship
- incarcerated
- under psychiatric care
- admitted to a healthcare or social institution
Exclusion
Key Trial Info
Start Date :
September 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 16 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07163338
Start Date
September 16 2025
End Date
March 16 2028
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France